Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
AJNR Am J Neuroradiol ; 21(10): 1930-5, 2000.
Article in English | MEDLINE | ID: mdl-11110549

ABSTRACT

BACKGROUND AND PURPOSE: The choline (Cho)/creatine (Cr) ratio has been shown to be a reliable proton MR spectroscopy metabolic marker for differentiating squamous cell carcinoma (SCCA) from normal muscle in the upper aerodigestive tract. However, it is unclear whether the Cho/Cr ratio can be used to differentiate a malignant tumor from a benign neoplasm in the extracranial head and neck. Our purpose was to determine whether the Cho/Cr ratio can be used to differentiate benign from malignant tumors in this region. METHODS: In vitro one-dimensional proton MR spectroscopy (2,000/136,272 [TR/TE]) was performed at 11 T on tissue specimens obtained from glomus tumors (n = 3), inverting papilloma (n = 1), and schwannoma (n = 1). Cho/Cr area ratios were calculated and compared with similar, previously reported in vitro (11 T) findings and with samples of SCCA and normal muscle. RESULTS: The Cho/Cr ratio was elevated in relation to muscle in all benign tumors at TE = 136 (glomus tumors = 4.52, inverting papilloma = 3.85, schwannoma = 2.2) and at TE = 272 (glomus tumors = 8.01, inverting papilloma = 2.1, schwannoma = 4.28). The average Cho/Cr ratio for benign lesions was 3.92 (TE = 136) and 6.11 (TE = 272). The Cho/Cr ratio was significantly higher in benign tumors than in both SCCA and muscle. The average Cho/Cr ratio for muscle at TEs of 136 and 272 was 1.16 and 1.31, respectively, whereas for SCCA the average Cho/Cr ratio at TEs of 136 and 272 was 1.67 and 2.45, respectively. CONCLUSION: In our small group, the Cho/Cr ratio was significantly higher in benign tumors than in muscle and SCCA of the extracranial head and neck.


Subject(s)
Carcinoma, Squamous Cell/metabolism , Carcinoma, Squamous Cell/pathology , Choline/metabolism , Creatine/metabolism , Gastrointestinal Neoplasms/metabolism , Gastrointestinal Neoplasms/pathology , Magnetic Resonance Spectroscopy , Muscles/metabolism , Area Under Curve , Diagnosis, Differential , Humans , Prospective Studies , Statistics, Nonparametric
2.
Semin Ultrasound CT MR ; 21(6): 434-51, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11138633

ABSTRACT

Magnetic resonance spectroscopy (MRS) has been shown to be an effective noninvasive diagnostic tool that can be used to monitor serially biochemical and metabolic changes in serial disease processes that affect the brain. MRS is now a clinical tool that is reimbursable. This article reviews MRS physics, techniques, pulse sequences, and the clinical applications of MRS.


Subject(s)
Brain Diseases/diagnosis , Brain/pathology , Magnetic Resonance Spectroscopy , Brain/metabolism , Brain Diseases/metabolism , Humans
SELECTION OF CITATIONS
SEARCH DETAIL
...